GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tandem Diabetes Care Inc (NAS:TNDM) » Definitions » ROE %

Tandem Diabetes Care (Tandem Diabetes Care) ROE % : -38.24% (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Tandem Diabetes Care ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Tandem Diabetes Care's annualized net income for the quarter that ended in Dec. 2023 was $-120.0 Mil. Tandem Diabetes Care's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $313.8 Mil. Therefore, Tandem Diabetes Care's annualized ROE % for the quarter that ended in Dec. 2023 was -38.24%.

The historical rank and industry rank for Tandem Diabetes Care's ROE % or its related term are showing as below:

TNDM' s ROE % Range Over the Past 10 Years
Min: -290.04   Med: -59.08   Max: 3.89
Current: -64.13

During the past 13 years, Tandem Diabetes Care's highest ROE % was 3.89%. The lowest was -290.04%. And the median was -59.08%.

TNDM's ROE % is ranked worse than
81.01% of 811 companies
in the Medical Devices & Instruments industry
Industry Median: 0.29 vs TNDM: -64.13

Tandem Diabetes Care ROE % Historical Data

The historical data trend for Tandem Diabetes Care's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tandem Diabetes Care ROE % Chart

Tandem Diabetes Care Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.17 -12.25 3.89 -21.67 -59.08

Tandem Diabetes Care Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.72 -127.26 -42.85 -40.99 -38.24

Competitive Comparison of Tandem Diabetes Care's ROE %

For the Medical Devices subindustry, Tandem Diabetes Care's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tandem Diabetes Care's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's ROE % distribution charts can be found below:

* The bar in red indicates where Tandem Diabetes Care's ROE % falls into.



Tandem Diabetes Care ROE % Calculation

Tandem Diabetes Care's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-222.611/( (439.947+313.632)/ 2 )
=-222.611/376.7895
=-59.08 %

Tandem Diabetes Care's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-120.008/( (314+313.632)/ 2 )
=-120.008/313.816
=-38.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Tandem Diabetes Care  (NAS:TNDM) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-120.008/313.816
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-120.008 / 787.184)*(787.184 / 946.2835)*(946.2835 / 313.816)
=Net Margin %*Asset Turnover*Equity Multiplier
=-15.25 %*0.8319*3.0154
=ROA %*Equity Multiplier
=-12.69 %*3.0154
=-38.24 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-120.008/313.816
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-120.008 / -125.24) * (-125.24 / -140.24) * (-140.24 / 787.184) * (787.184 / 946.2835) * (946.2835 / 313.816)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9582 * 0.893 * -17.82 % * 0.8319 * 3.0154
=-38.24 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Tandem Diabetes Care ROE % Related Terms

Thank you for viewing the detailed overview of Tandem Diabetes Care's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tandem Diabetes Care (Tandem Diabetes Care) Business Description

Traded in Other Exchanges
Address
11075 Roselle Street, San Diego, CA, USA, 92121
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. Nearly three quarters of total revenue is derived from the U.S., with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Executives
Dick Allen director 11045 ROSELLE STREET, SAN DIEGO CA 92121
Shannon Marie Hansen officer: SVP & General Counsel C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Leigh Vosseller officer: Senior Vice President and CFO C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Kathleen Mcgroddy-goetz director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Peyton R Howell director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
David B Berger officer: GENERAL COUNSEL 11045 ROSELLE STREET, SAN DIEGO CA 92121
Malagueira Joao Paulo Falcao director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Myoungil Cha director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Kim D Blickenstaff director, officer: PRESIDENT AND CEO C/O MEDIVATION, INC., 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94105
John F Sheridan officer: EXECUTIVE VP AND COO C/O TANDEM DIABETES CARE, INC., 11045 ROSELLE STREET, SAN DIEGO CA 92121
Christopher J Twomey director 4767 NEXUS CENTRE DRIVE, SAN DIEGO CA 92121
Rebecca B Robertson director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
James Leal officer: SVP, Operations C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Elizabeth Anne Gasser officer: EVP, Chief Strategy Officer C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Susan Morrison officer: CAO 11045 ROSELLE STREET, SAN DIEGO CA 92121

Tandem Diabetes Care (Tandem Diabetes Care) Headlines

From GuruFocus